Investment Analysts’ Recent Ratings Updates for G1 Therapeutics (GTHX)

A number of research firms have changed their ratings and price targets for G1 Therapeutics (NASDAQ: GTHX):

  • 3/15/2018 – G1 Therapeutics was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 3/13/2018 – G1 Therapeutics had its price target raised by analysts at Needham & Company LLC to $42.00. They now have a “buy” rating on the stock.
  • 3/8/2018 – G1 Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 3/7/2018 – G1 Therapeutics had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $48.00 price target on the stock. They wrote, “On Monday before market open, G1 announced positive topline data from the Phase 2a study of trilaciclib in combination with etoposide + carboplatin for patients with Extensive-stage SCLC (1st Line). We think that the Phase 2a study hit the important safety endpoints and set the company up well for later-line data with SCLC and metastatic Triple Negative Breast Cancer expected during 2H2018. Importantly, mgmt. indicated that they would use the strength of the 1st Line SCLC Phase2a data to begin discussions with regulators, which could accelerate the timeline versus awaiting data from the other studies during 2H2018. We reiterate our Buy rating and raise our PT to $48 from $38 as the topline release de-risks our assumptions around SCLC.””
  • 3/6/2018 – G1 Therapeutics had its “overweight” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a $39.00 price target on the stock, up previously from $33.00.
  • 3/5/2018 – G1 Therapeutics had its “buy” rating reaffirmed by analysts at Cowen Inc.
  • 2/28/2018 – G1 Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 2/26/2018 – G1 Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company’s product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. “
  • 2/22/2018 – G1 Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 2/22/2018 – G1 Therapeutics had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $38.00 price target on the stock.
  • 2/8/2018 – G1 Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company’s product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. “
  • 2/5/2018 – G1 Therapeutics had its price target raised by analysts at JPMorgan Chase & Co. to $30.00.
  • 2/3/2018 – G1 Therapeutics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 1/23/2018 – G1 Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.

Shares of G1 Therapeutics Inc (NASDAQ:GTHX) traded down $0.61 during midday trading on Friday, hitting $36.04. The company had a trading volume of 407,937 shares, compared to its average volume of 180,055. G1 Therapeutics Inc has a 52 week low of $12.04 and a 52 week high of $39.48.

How to Become a New Pot Stock Millionaire

G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings data on Wednesday, February 21st. The company reported ($0.60) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.02). research analysts anticipate that G1 Therapeutics Inc will post -2.47 earnings per share for the current year.

In related news, insider Rajesh Malik sold 3,776 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $22.96, for a total transaction of $86,696.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Mark A. Velleca sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $20.01, for a total value of $150,075.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 21,078 shares of company stock worth $508,585.

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Receive News & Ratings for G1 Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply